Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.

Sauter M, Uhl P, Burhenne J, Haefeli WE

Journal of pharmaceutical and biomedical analysis27 Mar 2020Cited by 5 (Europe PMC)

PMID32353679DOI10.1016/j.jpba.2020.113276PepBankPUB-32353679

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
After oral administration to beagle dogs, plasma bremelanotide concentrations indicated minimal oral absorption.
In plain wordsIn dogs, very little bremelanotide entered the blood after it was given by mouth.
Peptide
Bremelanotide (PT-141)
Outcome
Not applicableOral plasma bremelanotide absorption
Study
beagle dogn: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · oralAs given in this study (beagle dog).
Source sentences
Summary
The ultra-sensitive assay was applied to the quantification of bremelanotide plasma concentrations after oral administration to beagle dogs, which indicated minimal oral absorption.
Report a problemFND-3235367906

Studies that did not test the peptide alone5

In this study, Bremelanotide (PT-141) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Bremelanotide (PT-141).

02LabNot a test of Bremelanotide (PT-141) aloneOther designOther
A validated UHPLC-MS/MS assay quantified bremelanotide in 100 μL of plasma with a lower limit of quantification of 10 pg/mL (9.8 pM).
In plain wordsResearchers built a very sensitive lab test that measures tiny amounts of bremelanotide in blood plasma.
Peptide
Bremelanotide (PT-141)
Outcome
Not applicableUHPLC-MS/MS assay lower limit of quantification
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LLOQ
10 pg/mL
plasma
LLOQ
9.8 pM
plasma
Source sentences
Summary
we established a UHPLC-MS/MS assay with an LLOQ of 10 pg/mL (9.8 pM)
In this study, Bremelanotide (PT-141) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bremelanotide (PT-141).
Report a problemFND-3235367901
03LabNot a test of Bremelanotide (PT-141) aloneOther designOther
The bremelanotide assay was linear over 10-10,000 pg/mL with correlation coefficients above 0.99.
In plain wordsIn lab tests, the bremelanotide assay gave results that tracked concentration closely over its calibrated range.
Peptide
Bremelanotide (PT-141)
Outcome
Not applicableAssay linearity
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Calibrated range lower limit
10 pg/mL
plasma
Correlation coefficient
0.99
calibration
Source sentences
Summary
The calibrated concentration range of 10-10,000 pg/mL was linear showing correlation coefficients > 0.99.
In this study, Bremelanotide (PT-141) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bremelanotide (PT-141).
Report a problemFND-3235367902
04LabNot a test of Bremelanotide (PT-141) aloneOther designOther
Within the calibrated range, interday and intraday accuracy of the bremelanotide assay was 88.9-100.0 % with precision below 8 %.
In plain wordsIn lab tests, the bremelanotide assay was accurate and repeatable within its calibrated range.
Peptide
Bremelanotide (PT-141)
Outcome
Not applicableAssay accuracy and precision in calibrated range
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Accuracy
88.9 to 100%
interday and intraday
Precision
< 8%
interday and intraday
Source sentences
Summary
In the calibrated range, interday and intraday accuracy ranged from 88.9-100.0 % with corresponding precision < 8 %.
In this study, Bremelanotide (PT-141) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bremelanotide (PT-141).
Report a problemFND-3235367903
05LabNot a test of Bremelanotide (PT-141) aloneOther designOther
At the lower limit of quantification, the bremelanotide assay had accuracy of 93.6-100.8 % with precision below 11 %.
In plain wordsIn lab tests, the bremelanotide assay stayed accurate and repeatable at its lowest measurable level.
Peptide
Bremelanotide (PT-141)
Outcome
Not applicableAssay accuracy and precision at LLOQ
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Accuracy
93.6 to 100.8%
LLOQ
Precision
< 11%
LLOQ
Source sentences
Summary
Accuracy at the LLOQ ranged from 93.6-100.8 % with corresponding precision < 11 %.
In this study, Bremelanotide (PT-141) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bremelanotide (PT-141).
Report a problemFND-3235367904
06LabNot a test of Bremelanotide (PT-141) aloneOther designOther
A dilution quality control showed accurate quantification of 10-fold diluted plasma samples, extending the assay to 100,000 pg/mL.
In plain wordsIn lab tests, diluted plasma samples were still measured accurately, so the assay covers higher bremelanotide concentrations too.
Peptide
Bremelanotide (PT-141)
Outcome
Not applicableDilution QC accuracy and precision
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Accuracy
99.4%
10-fold diluted plasma
Precision
< 6%
10-fold diluted plasma
Source sentences
Summary
Because of the validity of a dilution QC that showed accurate quantification of 10-fold diluted plasma samples (accuracy 99.4 %, precision < 6 %), the assay is suitable for bremelanotide quantification in its effective concentration range up to 100,000 pg/mL.
In this study, Bremelanotide (PT-141) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Bremelanotide (PT-141).
Report a problemFND-3235367905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.